One Year Follow-up from RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response

Sustained levels of RSV F antibody and palivizumab-competing antibody responses demonstrated over a 4 to 6 month period  Results support accelerating development plans for “seasonal” elderly RSV vaccine  Phase 2 clinical trial in elderly anticipated to start in late-2014/early-2015 May 12, 2014 Novavax, Inc. today announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) …

Novavax Announces Positive Top-Line Data from Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate in Women of Childbearing Age

Vaccine candidate was well-tolerated with no vaccine-related serious adverse events Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant Women with the lowest baseline levels of RSV neutralizing antibodies had the largest increases following immunization, consistent with prior data Palivizumab-like antibodies exceeded levels observed in previous trials  High levels of antibodies developed within 14 days after …

Researchers Develop Key to Effective RSV Vaccine: HIV and influenza next up

Scientists from the Scripps Research Institute, Calafornia, US, have created vital ingredients for an effective vaccination against respiratory syncytial virus (RSV) through a new method they have developed for producing artificial proteins. As reported in Nature on February the 5th, using a ‘rational design’ method researchers produced designer proteins which stimulate the production of the desired virus-neutralizing antibodies for RSV in …

Golden opportunity: Nanotech RSV vaccine based on gold particles

Researchers writing in Nanotechnology have developed a novel vaccination method to combat the respiratory syncytial virus (RSV) using tiny gold nanorods to mimic the virus. The nanorod constructs, which are just 21 nanometres wide and 57 nanometres long, are almost exactly the same shape and size as the RSV virus and are coated in the virus' fusion (F) protein. The …

Novavax announce promising RSV vaccine Phase II results

Novavax have reported positive results of a Phase II clinical trial of its respiratory syncytial virus (RSV) vaccine candidate as a maternal immunization strategy. Novavax say that the randomized, blinded, placebo-controlled, dose-ranging Phase II clinical trial of the RSV F protein nanoparticle vaccine candidate accomplished the trial's protocol-specified objectives and supports progression to the next stage. Maternal immunization is a …

Respiratory syncytial virus (RSV): Potential significant opportunity for effective vaccine

  Pioneering new research into respiratory syncytial virus (RSV) may have overcome the barriers that have impeded the development of an effective vaccine against the deadly virus. RSV is a virus that causes lower respiratory tract infections and is a major cause of childhood morbidity and mortality worldwide. Attempts to develop vaccines against the virus in the 1960s were dogged …